首页> 外文期刊>Heart >Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy
【24h】

Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy

机译:肥厚型心肌病的心肺运动测试和心脏猝死风险

获取原文
获取原文并翻译 | 示例
       

摘要

Background In hypertrophic cardiomyopathy (HCM), most of the factors associated with the risk of sudden cardiac death (SCD) are also involved in the pathophysiology of exercise limitation. The present multicentre study investigated possible ability of cardiopulmonary exercise test in improving contemporary strategies for SCD risk stratification. Methods A total of 623 consecutive outpatients with HCM, from five tertiary Italian HCM centres, were recruited and prospectively followed, between September 2007 and April 2015. The study composite end point was SCD, aborted SCD and appropriate implantable cardioverter defibrillator (ICD) interventions. Results During a median follow-up of 3.7 years (25th-75th centile: 2.2-5.1 years), 25 patients reached the end point at 5 years (3 SCD, 4 aborted SCD, 18 appropriate ICD interventions). At multivariate analysis, ventilation versus carbon dioxide relation during exercise (VE/VCO_2 slope) remains independently associated to the study end point either when challenged with the 2011 American College of Cardiology Foundation/American Heart Association guidelines-derived score (C index 0.748) or with the 2014 European Society of Cardiology guidelines-derived score (C index 0.750). AVE/VCO_2 slope cut-off value of 31 showed the best accuracy in predicting the SCD end point within the entire HCM study cohort (sensitivity 64%, specificity 72%, area under the curve 0.72). Conclusions Our data suggest that the VE/VCO_2 slope might improve SCD risk stratification, particularly in those HCM categories classified at low-intermediate SCD risk according to contemporary guidelines. There is a need for further larger studies, possibly on independent cohorts, to confirm our preliminary findings.
机译:背景在肥厚型心肌病(HCM)中,与突发性心脏猝死(SCD)风险相关的大多数因素也与运动受限的病理生理有关。当前的多中心研究调查了心肺运动测试在改善当代SCD危险分层策略中的可能能力。方法自2007年9月至2015年4月,共招募了意大利五个HCM中心的623名HCM门诊患者,并对其进行了前瞻性随访。研究的综合终点为SCD,SCD终止和适当的植入式心脏复律除颤器(ICD)干预。结果在平均3.7年(25-75岁百分位数:2.2-5.1年)中,有25名患者在5年时达到终点(3例SCD,4例中止SCD,18例适当的ICD干预)。在多变量分析中,当受到2011年美国心脏病学会基金会/美国心脏协会指南得出的评分(C指数0.748)质疑时,运动期间通气与二氧化碳的关系(VE / VCO_2斜率)仍独立地与研究终点相关。根据2014年欧洲心脏病学会指南得出的分数(C指数0.750)。 AVE / VCO_2斜率截止值为31,在预测整个HCM研究队列中的SCD终点时显示出最高的准确度(敏感性64%,特异性72%,曲线下面积0.72)。结论我们的数据表明VE / VCO_2斜率可能会改善SCD风险分层,尤其是在根据当代指南归类为低中度SCD风险的HCM类别中。需要进一步的大规模研究(可能在独立队列中)以确认我们的初步发现。

著录项

  • 来源
    《Heart》 |2016年第8期|602-609|共8页
  • 作者单位

    Department of Clinical and Molecular Medicine, University of Rome 'La Sapienza', Rome, Italy,Department of Clinical and Molecular Medicine, 'Sapienza' University, Rome, Italy, Cardiology Unit, Sant' Andrea Hospital, Via di Grottarossa 1037, Rome 00189, Italy;

    Cardiologia SUN, Monaldi Hospital, Ⅱ University of Naples, Naples, Italy;

    Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, San Camillo-Forlanini Hospital, Rome, Italy;

    Centro Cardiologico Monzino, IRCCS, Milan, Italy,Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;

    Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, San Camillo-Forlanini Hospital, Rome, Italy;

    Department of Cardiology, University of Foggia, Foggia, Italy;

    Department of Clinical and Molecular Medicine, University of Rome 'La Sapienza', Rome, Italy;

    Department of Clinical and Molecular Medicine, University of Rome 'La Sapienza', Rome, Italy;

    Department of Clinical and Molecular Medicine, University of Rome 'La Sapienza', Rome, Italy;

    Cardiologia SUN, Monaldi Hospital, Ⅱ University of Naples, Naples, Italy;

    Cardiologia SUN, Monaldi Hospital, Ⅱ University of Naples, Naples, Italy;

    Department of Clinical and Molecular Medicine, University of Rome 'La Sapienza', Rome, Italy;

    Department of Scienze Economiche, politiche e delle lingue moderne, Libera Universita SS Maria Assunta, Rome, Italy,Centre for Innovation and Leadership in Health Sciences, University of Southampton, Southampton, UK;

    Department of Clinical and Molecular Medicine, University of Rome 'La Sapienza', Rome, Italy,IRCCS, Neuromed, Pozzilli (IS), Italy;

    Department of Clinical and Molecular Medicine, University of Rome 'La Sapienza', Rome, Italy;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 01:32:52

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号